2021
DOI: 10.1007/s10989-021-10248-2
|View full text |Cite
|
Sign up to set email alerts
|

Prophylactic Application of MA-[d-Leu-4]-OB3, a Small Molecule Synthetic Peptide Leptin Mimetic, Prevents or Slows the Progression of Obesity, Insulin Resistance, and Cognitive Impairment in a Mouse Model of Type 2 Diabetes Mellitus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 26 publications
0
3
0
Order By: Relevance
“…A recently-published follow-up study indicated that the mechanism of action by which MA-[D-Leu-4]-OB3 improves cognitive function in these mouse models appears to be related to its ability to enhance insulin sensitivity peripherally and in the brain, and to reduce TNF-α-induced neurodegeneration (Hirschstein et al, 2020). Most recently, the prophylactic capacity of MA-[D-Leu-4]-OB3 to prevent or slow the progression of obesity, insulin resistance, and cognitive impairment in a mouse model of T2DM has been reported (Chua et al, 2021). The ability of MA-[D-Leu-4]-OB3 to improve serum lipid profiles in mouse models of T1DM and T2DM (Hirschstein et al, 2021), suggests an additional application targeted toward reducing the risk of adverse cardiovascular events in humans that are associated with both T1DM and T2DM.…”
Section: Assessing the Effects Of Leptin Mimetics On Cognitive Functionmentioning
confidence: 97%
“…A recently-published follow-up study indicated that the mechanism of action by which MA-[D-Leu-4]-OB3 improves cognitive function in these mouse models appears to be related to its ability to enhance insulin sensitivity peripherally and in the brain, and to reduce TNF-α-induced neurodegeneration (Hirschstein et al, 2020). Most recently, the prophylactic capacity of MA-[D-Leu-4]-OB3 to prevent or slow the progression of obesity, insulin resistance, and cognitive impairment in a mouse model of T2DM has been reported (Chua et al, 2021). The ability of MA-[D-Leu-4]-OB3 to improve serum lipid profiles in mouse models of T1DM and T2DM (Hirschstein et al, 2021), suggests an additional application targeted toward reducing the risk of adverse cardiovascular events in humans that are associated with both T1DM and T2DM.…”
Section: Assessing the Effects Of Leptin Mimetics On Cognitive Functionmentioning
confidence: 97%
“…The prophylactic potential of MA-[D-Leu-4]-OB3 was also recently confirmed by its ability to prevent and/or slow the progression of obesity, insulin resistance, and cognitive impairment in normal C57BL/6 mice placed on a high-fat diet immediately after weaning. 21 In the 2 studies reported here, we provide evidence that oral delivery of MA-[D-Leu-4]-OB3, previously shown to modulate energy balance, glycemic control, serum lipids, and cognitive function in mouse models of leptin deficiency and leptin resistance, does not induce anorexia, severe weight loss, hypoglycemia, cognitive dysfunction, or any physical or behavioral clinical indicators of toxicity when given to male or female C57BL/6 mice at concentrations significantly higher than the minimal effective dose, or for extended periods of time.…”
Section: Introductionmentioning
confidence: 99%
“…The prophylactic potential of MA-[D-Leu-4]-OB3 was also recently confirmed by its ability to prevent and/or slow the progression of obesity, insulin resistance, and cognitive impairment in normal C57BL/6 mice placed on a high-fat diet immediately after weaning. 21…”
Section: Introductionmentioning
confidence: 99%